Key Insights

Highlights

Treatment Research

5 treatments under study, led by Active Investigational Medicinal Product Imp Contains 400 Mg Of Moxifloxacin 1 X 400 Mg Tablet Moxifloxacin 400 Mg Tablets Which Are Authorized Medicinal Products Are Sourced From Legal Supply Chain Of Medicinal Products At Eu And Used For Preparation Of The Active Imp Tablets Are Masked By Over Encapsulation With Hard Gelatine Capsule 1 X 400 Mg In A Capsule To Maintain Blinding Matching Placebo Imp Capsule Are Prepared Containing Microcrystalline Cellulose

Research Leaders

11 sponsors active, led by Hospital Universitario Virgen de la Arrixaca

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
Phase 4 (1)

Trial Status

Not Yet Recruiting3
Unknown1

Clinical Trials (4)

Research Network

Common Treatments

  • Active Investigational Medicinal Product Imp Contains 400 Mg Of Moxifloxacin 1 X 400 Mg Tablet Moxifloxacin 400 Mg Tablets Which Are Authorized Medicinal Products Are Sourced From Legal Supply Chain Of Medicinal Products At Eu And Used For Preparation Of The Active Imp Tablets Are Masked By Over Encapsulation With Hard Gelatine Capsule 1 X 400 Mg In A Capsule To Maintain Blinding Matching Placebo Imp Capsule Are Prepared Containing Microcrystalline Cellulose1
  • Clinical Pathway With Fasttrack1
  • Moxifloxacin1
  • Ketorolacgrindeks 30 Mgml Šķīdums Injekcijām1
  • Postoperative Usual Protocol1

Active Sponsors

  • Hospital Universitario Virgen de la Arrixaca1
  • Jyväskylä Central Hospital1
  • Päijänne Tavastia Central Hospital1
  • Seinajoki Central Hospital1
  • Turku University Hospital1

Top Investigators

Activity Timeline